<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03088176</url>
  </required_header>
  <id_info>
    <org_study_id>WCC20149189</org_study_id>
    <nct_id>NCT03088176</nct_id>
  </id_info>
  <brief_title>Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma</brief_title>
  <official_title>A Phase 1b Trial of Talimogene Laherparepvec in Combination With Dabrafenib and Trametinib in Advanced Melanoma With an Activating BRAF Mutation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>West Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Tennessee Health Science Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>West Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine safety and tolerability of the combination of&#xD;
      talimogene laherparepvec in combination with dabrafenib and trametinib in BRAF mutated&#xD;
      advanced melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      While targeted therapies can successfully block oncogenic signaling in BRAF mutant melanoma,&#xD;
      activation of an immune response with agents such as talimogene laherparepvec can induce&#xD;
      durable responses in a subset of patients. Combining BRAF inhibitors and immunotherapy may&#xD;
      specifically target the BRAF driver mutation in the tumor cells and potentially sensitize the&#xD;
      immune system to target tumors.&#xD;
&#xD;
      The study will enroll up to 20 patients with advanced melanoma and activating mutations in&#xD;
      the BRAF gene for the local administration of talimogene laherparepvec in conjunction with&#xD;
      oral therapy with dabrafenib and trametinib, to describe the safety and tolerability of this&#xD;
      combination.&#xD;
&#xD;
      Talimogene laherparepvec will be administered by intralesional injection into injectable&#xD;
      cutaneous, subcutaneous, or nodal lesions with or without image ultrasound guidance.&#xD;
      Talimogene laherparepvec will not be administered into any visceral organ or mucosal membrane&#xD;
      lesions. The initial dose of talimogene laherparepvec is up to 4.0 mL of 106 plaque forming&#xD;
      units (PFU)/mL. Subsequent doses of talimogene laherparepvec are up to 4.0 mL of 108 PFU/mL.&#xD;
      The second dose of talimogene laherparepvec (the first dose of the 108 PFU formulation), will&#xD;
      be administered at least 21 days following the initial dose. Subsequent doses will be given&#xD;
      approximately every 2 weeks.&#xD;
&#xD;
      Dabrafenib at a dose of 150mg will be self-administered orally twice per day. Trametinib at a&#xD;
      dose 2mg will be self-administered orally once per day.&#xD;
&#xD;
      Subjects will be evaluated by physical exam at the beginning of Cycle 1 (Week 1), Cycle 2&#xD;
      (Week 4), Cycle 3 (Week 6), Cycle 4 (Week 8), and every two cycles thereafter. Subjects will&#xD;
      be evaluated for dose-limiting toxicities (defined in protocol) at Cycle 2 (Week 4), Cycle 3&#xD;
      (Week 6), and Cycle 4 (Week 8). Efficacy evaluation will be performed by tumor measurements&#xD;
      using clinical assessment, CT or PET/CT every 4 cycles with the first non-baseline&#xD;
      measurement prior to Cycle 4. Tumor response will be evaluated using RECIST 1.1. Adverse&#xD;
      events will be recorded and graded using the Common Terminology Criteria for Adverse Events&#xD;
      Version 4.0 (CTCAE v4.0). Other safety assessments will include clinical laboratory values&#xD;
      and physical exam findings. Reporting of adverse events, serious adverse events, and&#xD;
      documentation of concomitant medications will occur as needed and at every cycle. Biopsy of a&#xD;
      melanoma lesion (preferably uninjected) should occur at least one day prior to Cycle 4 (Week&#xD;
      8). Blood for biomarker analysis will be obtained immediately prior to the on-treatment&#xD;
      biopsy, or if the on-treatment biopsy cannot be performed, immediately prior to Cycle 4 (Week&#xD;
      8).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 25, 2017</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Phase 1b single arm single dose level</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>No masking</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Dose Limiting Toxicities (DLT)</measure>
    <time_frame>2 years</time_frame>
    <description>Number of DLT seen in the subject population</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>4 years</time_frame>
    <description>per RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>4 years</time_frame>
    <description>per RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in tumor burden</measure>
    <time_frame>4 years</time_frame>
    <description>Best change in tumor diameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response</measure>
    <time_frame>4 years</time_frame>
    <description>In responding patients, time from first dose to achieving objective response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>4 years</time_frame>
    <description>In responding patients, time from first evidence of objective response until progression or end of study</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Lesion-level objective response</measure>
    <time_frame>4 years</time_frame>
    <description>Change in diameters of individual lesions</description>
  </other_outcome>
  <other_outcome>
    <measure>Biomarker analysis</measure>
    <time_frame>4 years</time_frame>
    <description>Exploratory analysis including number of participants with changes in CD8+ tumor infiltrating lymphocytes between pre-study and on-study biopsies</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Melanoma</condition>
  <condition>BRAF Gene Mutation</condition>
  <arm_group>
    <arm_group_label>Combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Talimogene laherperepvec intratumoral injection up to 4ml of 10^6 PFU/mL on Day 1, followed by up to 4mL of 10^8 PFU/mL 3 weeks later, followed by every 2 weeks thereafter for up to two years.&#xD;
Dabrafenib 150mg orally twice daily for up to two years Trametinib 2mg orally once daily for up to two years</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Talimogene Laherparepvec 1 Million Pfu/Ml Inj,Susp,1Ml,Vil</intervention_name>
    <description>Up to 4mL administered on C1D1 intratumorally</description>
    <arm_group_label>Combination</arm_group_label>
    <other_name>Imlygic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Talimogene Laherparep 100 Mil Pfu/Ml 1Ml</intervention_name>
    <description>Up to 4 ML administered on Week 4 Day 1 and every 2 weeks thereafter</description>
    <arm_group_label>Combination</arm_group_label>
    <other_name>Imlygic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabrafenib</intervention_name>
    <description>150mg PO qday</description>
    <arm_group_label>Combination</arm_group_label>
    <other_name>Tafinlar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trametinib</intervention_name>
    <description>2mg PO qday</description>
    <arm_group_label>Combination</arm_group_label>
    <other_name>Mekinist</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age â‰¥ 18&#xD;
&#xD;
          2. Primary or recurrent Stage IIIB to IVM1c melanoma for whom surgery is not recommended&#xD;
&#xD;
          3. Activating BRAF mutation (limited to V600E or V600K mutations if being treated&#xD;
             first-line, but can include any well-defined BRAF mutation after failure of prior&#xD;
             immunotherapy)&#xD;
&#xD;
          4. Measurable disease defined as follows: At least one melanoma lesion that can be&#xD;
             accurately and serially measured in one dimension and for which the longest diameter&#xD;
             is â‰¥10 mm as measured by calipers, CT scan, or MRI.&#xD;
&#xD;
             a. If all lesions are lymph nodes, at least one node must be able to be accurately and&#xD;
             serially measured in two dimensions, and the short-axis must be â‰¥15mm.&#xD;
&#xD;
          5. Injectable disease (defined as at least 1cm of disease in areas suitable for injection&#xD;
             including cutaneous, subcutaneous, or nodal lesions)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior therapy with talimogene laherparepvec&#xD;
&#xD;
          2. Prior therapy with the combination of dabrafenib and trametinib&#xD;
&#xD;
          3. Evidence of clinically significant immunosuppression such as the following:&#xD;
&#xD;
               1. Primary immunodeficiency state such as Severe Combined Immunodeficiency Disease&#xD;
&#xD;
               2. Concurrent opportunistic infection&#xD;
&#xD;
               3. Receiving chronic systemic immunosuppressive therapy (&gt; 2 weeks), including oral&#xD;
                  steroid doses &gt; 10mg/day of prednisone or equivalent except for management of&#xD;
                  adverse events and CNS metastases during the course of the study. Subjects&#xD;
                  requiring intermittent use of bronchodilators or local steroid injections are not&#xD;
                  excluded.&#xD;
&#xD;
          4. Active herpes infection, herpes requiring chronic anti-herpetic therapy, or&#xD;
             complications of prior herpetic infection (such as keratitis or encephalitis)&#xD;
&#xD;
          5. Chronic use of immunosuppressants or steroids (defined as prednisone 10mg/day or&#xD;
             equivalent)&#xD;
&#xD;
          6. Clinically active cerebral metastases&#xD;
&#xD;
          7. History or evidence of melanoma associated with immunodeficiency states&#xD;
&#xD;
          8. History of other malignancy within prior 24 months with the exception of breast or&#xD;
             bladder carcinoma in situ, and non-melanomatous skin cancer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>West Cancer Center</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>March 7, 2017</study_first_submitted>
  <study_first_submitted_qc>March 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2017</study_first_posted>
  <last_update_submitted>October 9, 2020</last_update_submitted>
  <last_update_submitted_qc>October 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Melanoma</keyword>
  <keyword>BRAF inhibitor</keyword>
  <keyword>Intratumoral injection</keyword>
  <keyword>Talimogene laherparepvec</keyword>
  <keyword>MEK inhibitor</keyword>
  <keyword>dabrafenib</keyword>
  <keyword>trametinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trametinib</mesh_term>
    <mesh_term>Dabrafenib</mesh_term>
    <mesh_term>Talimogene laherparepvec</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Data will be de-identified before publication or sharing with external entities or researchers</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

